Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

venglustat

Rare Disease news

Rare Diseases Today—March 26, 2026

This week’s Rare Diseases update highlights regulatory designations, new…

Rare Disease news

Rare Disease Video Recap—February 12, 2026

This biweekly Rare Disease Video Recap covers regulatory actions, late-stage…

Neuroscience

Neuroscience Video Recap—February 4, 2026

This biweekly Neuroscience video recap covers key updates, including regulatory…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
LucidWargames
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Lucid Diligence Brief: Arrowhead ARO-PNPLA3 licensed to Madrigal
Obesity Today—May 5, 2026
Endocrinology Today—May 5, 2026
Lucid Diligence Brief: Latus Bio $97 million Series A
Lucid Diligence Brief: UCB acquisition of Candid Therapeutics

Tags

AAV MYO2 ART5803 B7-H3 Breztri Aerosphere CanSino cardiovascular risk factors Cas12 Cenrifki cladribine Corcept CryptiVax-1001 cutaneous T-cell lymphoma cytomegalovirus Dapagliflozin data linkage Dexcom Duchesnay Evkeeza FSHD Garmin Global Burden of Disease Hanmi HM17321 heart failure congestion Kisunla MannKind Miltenyi Bioindustry multispecific antibodies Nature Immunology neurological epidemiology PANTHERx Rare Pelareorep personalized cancer vaccine QRX009 Redx Pharma Reflow Medical Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma risperidone LAI Saudi Arabia Systemic lupus erythematosus TYK2 inhibitor UnitedHealthcare UZEDY ViGenCell WINREVAIR Yashoda

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Lucid Diligence Brief: Arrowhead ARO-PNPLA3 licensed to Madrigal
Obesity Today—May 5, 2026
Endocrinology Today—May 5, 2026
Lucid Diligence Brief: Latus Bio $97 million Series A
Lucid Diligence Brief: UCB acquisition of Candid Therapeutics

TAGS

AAV MYO2 ART5803 B7-H3 Breztri Aerosphere CanSino cardiovascular risk factors Cas12 Cenrifki cladribine Corcept CryptiVax-1001 cutaneous T-cell lymphoma cytomegalovirus Dapagliflozin data linkage Dexcom Duchesnay Evkeeza FSHD Garmin Global Burden of Disease Hanmi HM17321 heart failure congestion Kisunla MannKind Miltenyi Bioindustry multispecific antibodies Nature Immunology neurological epidemiology PANTHERx Rare Pelareorep personalized cancer vaccine QRX009 Redx Pharma Reflow Medical Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma risperidone LAI Saudi Arabia Systemic lupus erythematosus TYK2 inhibitor UnitedHealthcare UZEDY ViGenCell WINREVAIR Yashoda

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy